# Codex DNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/codex-dna

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.codexdna.com
- Total disclosed funding: $25M
- Latest round: Series A (Dec 19, 2019)
- Investors on record: 3

## About

Founded in 2011 as Synthetic Genomics Solutions, and based in California, US, Codex DNA, Inc., formerly SGI-DNA, Inc. operates as a provider of genomic tools that help scientists to discover, design, and build solutions for basic research, biomedical and industrial applications. The company was founded by Dan Gibson and Todd Nelson. In September 2019, Codex raised Series A funding, followed by another Series A funding in December 2019. In September 2019, the company also commercialized its synthetic biology solution, which incorporates the BioXp 3250 system. As of June 2021, the company had 101 employees and has installed roughly 160 BioXp systems across the world. In June 2021, Codex DNA, Inc. raised USD 107.2 million in an IPO, selling 6.7 million shares at USD 16 per share. It trades on Nasdaq under the ticker symbol DNAY.

The company offers BioXp, a DNA printer that improves the workflows for protein production and cell engineering, and Gibson Assembly Reagents, a cloning procedure that allows the joining of two or more fragments.

## Funding rounds

- Series A, Dec 19, 2019 — Northpond Ventures
- Series A, Sep 9, 2019, $25M — BroadOak Capital Partners, Oxford Finance, Northpond Ventures

## Investors

- BroadOak Capital Partners (https://capitalatlas.ai/funds/broadoak-capital-partners) — Series A
- Oxford Finance — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A